BeyondSpring (BYSI) Competitors $1.82 +0.06 (+3.41%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$1.82 0.00 (0.00%) As of 08/25/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BYSI vs. RNAC, NGNE, FHTX, AVIR, GLUE, DBVT, ACB, LFCR, PBYI, and VORShould you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Cartesian Therapeutics (RNAC), Neurogene (NGNE), Foghorn Therapeutics (FHTX), Atea Pharmaceuticals (AVIR), Monte Rosa Therapeutics (GLUE), DBV Technologies (DBVT), Aurora Cannabis (ACB), Lifecore Biomedical (LFCR), Puma Biotechnology (PBYI), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. BeyondSpring vs. Its Competitors Cartesian Therapeutics Neurogene Foghorn Therapeutics Atea Pharmaceuticals Monte Rosa Therapeutics DBV Technologies Aurora Cannabis Lifecore Biomedical Puma Biotechnology Vor Biopharma BeyondSpring (NASDAQ:BYSI) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Do insiders and institutionals believe in BYSI or RNAC? 40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, BYSI or RNAC? BeyondSpring has higher earnings, but lower revenue than Cartesian Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeyondSpring$1.75M41.94-$11.12MN/AN/ACartesian Therapeutics$38.91M7.52-$77.42M-$52.83-0.21 Does the media favor BYSI or RNAC? In the previous week, Cartesian Therapeutics had 1 more articles in the media than BeyondSpring. MarketBeat recorded 1 mentions for Cartesian Therapeutics and 0 mentions for BeyondSpring. Cartesian Therapeutics' average media sentiment score of 1.89 beat BeyondSpring's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment BeyondSpring Neutral Cartesian Therapeutics Very Positive Which has more volatility and risk, BYSI or RNAC? BeyondSpring has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Is BYSI or RNAC more profitable? Company Net Margins Return on Equity Return on Assets BeyondSpringN/A N/A N/A Cartesian Therapeutics N/A N/A -6.36% Do analysts prefer BYSI or RNAC? Cartesian Therapeutics has a consensus price target of $40.00, indicating a potential upside of 255.56%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryCartesian Therapeutics beats BeyondSpring on 9 of the 12 factors compared between the two stocks. Get BeyondSpring News Delivered to You Automatically Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BYSI vs. The Competition Export to ExcelMetricBeyondSpringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.99M$3.12B$5.81B$9.74BDividend YieldN/A2.24%4.40%4.08%P/E RatioN/A20.6430.1425.84Price / Sales41.94339.07432.88102.91Price / CashN/A43.2325.7828.79Price / Book-4.929.649.425.99Net Income-$11.12M-$54.08M$3.27B$265.29M7 Day Performance4.00%5.58%3.64%4.07%1 Month Performance-5.21%4.11%3.52%0.93%1 Year Performance-8.54%6.70%29.94%18.21% BeyondSpring Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BYSIBeyondSpringN/A$1.82+3.4%N/A-5.2%$70.99M$1.75M0.0080Positive NewsRNACCartesian Therapeutics2.5453 of 5 stars$11.02-2.3%$40.00+263.1%-18.2%$286.41M$1.03M-0.2164Positive NewsNGNENeurogene2.1658 of 5 stars$19.89-2.8%$46.17+132.2%-42.8%$283.76M$930K-4.6190Positive NewsFHTXFoghorn Therapeutics2.9045 of 5 stars$4.88-4.3%$10.67+118.5%-34.5%$279.26M$22.60M-4.15120Positive NewsAVIRAtea Pharmaceuticals1.685 of 5 stars$3.50-1.0%$6.00+71.7%-6.2%$277.36MN/A-2.1770GLUEMonte Rosa Therapeutics2.5464 of 5 stars$4.43-2.9%$15.33+246.1%-27.5%$273.60M$75.62M12.3190Positive NewsDBVTDBV Technologies2.7669 of 5 stars$9.89-1.1%$14.75+49.1%+112.8%$270.89MN/A-2.0780ACBAurora Cannabis0.799 of 5 stars$4.76-7.1%N/A-19.7%$269.57M$357.88M-25.131,130LFCRLifecore Biomedical0.7049 of 5 stars$7.16-3.2%$8.00+11.7%+26.5%$268.98M$128.87M-5.49690PBYIPuma Biotechnology3.9278 of 5 stars$5.20+3.7%$7.00+34.7%+96.5%$262.69M$238.06M5.32200High Trading VolumeVORVor Biopharma0.0914 of 5 stars$2.06+1.0%N/AN/A$260.97MN/A-0.15140Gap Up Related Companies and Tools Related Companies RNAC Competitors NGNE Competitors FHTX Competitors AVIR Competitors GLUE Competitors DBVT Competitors ACB Competitors LFCR Competitors PBYI Competitors VOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BYSI) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access